+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Infliximab"

Biosimilar Monoclonal Antibodies Market Report 2026 - Product Thumbnail Image

Biosimilar Monoclonal Antibodies Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Psoriasis Biosimilars Market Report 2026 - Product Thumbnail Image

Psoriasis Biosimilars Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
TNF Alpha Inhibitors Market Report 2026 - Product Thumbnail Image

TNF Alpha Inhibitors Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Arthritis Monoclonal Antibodies Market Report 2026 - Product Thumbnail Image

Arthritis Monoclonal Antibodies Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Remicade Biosimilar Market Report 2026 - Product Thumbnail Image

Remicade Biosimilar Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Ocular Immunosuppressants Market - Global Forecast 2026-2032 - Product Thumbnail Image

Ocular Immunosuppressants Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 180 Pages
  • Global
From
From
Autoimmune Monoclonal Antibody Market Report 2026 - Product Thumbnail Image

Autoimmune Monoclonal Antibody Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Psoriasis Market Report 2026 - Product Thumbnail Image

Psoriasis Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
Behcet's Disease Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Behcet's Disease Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
Kawasaki Disease Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Kawasaki Disease Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients. Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms. The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more